 |
66 Diseases |  |
14 Trials |
|
14 Trials |  |
518 News |  |
| «123456» |
- | Kinaction (masitinib) / AB Science
Journal: Tumor Necrosis Factor-α Is Required for Mast Cell-Mediated Host Immunity Against Cutaneous Staphylococcus aureus Infection. (Pubmed Central) - Sep 14, 2019
In addition, S. aureus-induced MC activation was dependent on the c-kit receptor-activated phosphoinositide 3-kinase (PI3K)/AKT/P65-nuclear factor (NF-κB) pathway, which was confirmed by treatment with Masitinib (a c-kit receptor inhibitor), Wortmannin (a PI3K inhibitor), and pyrrolidine dithiocarbamate (a NF-κB inhibitor), respectively. The present study identifies the critical role of MCs in the host defense against S. aureus infection.
- | Journal: Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. (Pubmed Central) - Sep 10, 2019
In addition, fluorocoxib A uptake correlated with the AB1010- and imatinib-induced COX-2 expression in the K9TCC#5Lilly xenografts in vivo. In conclusion, these results indicate that fluorocoxib A could be used for the monitoring the early responses to targeted therapies in COX-2-expressing bladder cancer.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Kinaction (masitinib) / AB Science
Journal: Identification and Characterization of Prescription Drugs that Change Levels of the Cholesterol Precursors 7-Dehydrocholesterol and Desmosterol. (Pubmed Central) - Aug 23, 2019
Evidence is provided that three tyrosine kinase inhibitors, imatinib, ponatinib and masitinib elevate desmosterol levels as well as other metabolites of DHCR24, the enzyme responsible for converting desmosterol to cholesterol. Additionally, the mechanism of action for ponatinib and masitinib was explored demonstrating that protein levels are down regulated as a result of treatment with these drugs.
- | Kinaction (masitinib) / AB Science, Radicava (edaravone) / Mitsubishi Tanabe
Why does @momfrates call for a @US_FDA petition for MASITINIB and EDARAVONE but not for #NurOwn? There is an @alsassociation conflict of interest with Gold Sponsors to not approve #NurOwn (Twitter) - Aug 18, 2019
- | Kinaction (masitinib) / AB Science
@EMA_News @IMMolecular @INFARMED_IP #masitinib #ELA #ALS #MND @saude_pt (Twitter) - Aug 12, 2019
- | Kinaction (masitinib) / AB Science
Journal: Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. (Pubmed Central) - Jul 11, 2019
Masitinib also normalized macrophage infiltration, as well as regressive changes in Schwann cells and capillary networks observed in advanced paralysis. These findings provide evidence for mast cell contribution to distal axonopathy and paralysis progression in ALS, a mechanism that can be therapeutically targeted by masitinib.
- || Kinaction (masitinib) / AB Science
Wait. Masitinib, the dog cancer drug? (Twitter) - Jun 27, 2019
- |||| Kinaction (masitinib) / AB Science
Trial primary completion date: Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jun 17, 2019
P3, N=721, Active, not recruiting, Sponsor: AB Science
These findings provide evidence for mast cell contribution to distal axonopathy and paralysis progression in ALS, a mechanism that can be therapeutically targeted by masitinib. Trial primary completion date: Apr 2019 --> Dec 2019
- |||| Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date: Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids (clinicaltrials.gov) - Apr 30, 2019
P3, N=420, Active, not recruiting, Sponsor: AB Science
Trial primary completion date: Apr 2019 --> Dec 2019 Trial completion date: Mar 2019 --> Jun 2020 | Trial primary completion date: Mar 2019 --> Jun 2019
- |||| Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 30, 2019
P3, N=656, Active, not recruiting, Sponsor: AB Science
Trial completion date: Mar 2019 --> Jun 2020 | Trial primary completion date: Mar 2019 --> Jun 2019 Trial completion date: Mar 2019 --> Sep 2020 | Trial primary completion date: Mar 2019 --> Sep 2019
- | Kinaction (masitinib) / AB Science
EMA Decides Fast-Track Fate Of Masitinib And Anthrax Antitoxin https://t.co/LCMU0c2x8T #PinkSheet (Twitter) - Mar 27, 2019
- | Kinaction (masitinib) / AB Science
Journal: Estrogen-induced transcription factor EGR1 regulates c-Kit transcription in the mouse uterus to maintain uterine receptivity for embryo implantation. (Pubmed Central) - Mar 25, 2019
c-Kit expression was significantly increased in the uterus on day 4 and administration of Masitinib, a c-Kit inhibitor, effectively interfered with embryo implantation. Collectively, our results showed that estrogen induces transcription factor EGR1 to regulate c-Kit transcription for uterine receptivity for embryo implantation in the mouse uterus.
- | Kinaction (masitinib) / AB Science
Enrollment change, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2019
P3, N=123, Terminated, Sponsor: AB Science
Collectively, our results showed that estrogen induces transcription factor EGR1 to regulate c-Kit transcription for uterine receptivity for embryo implantation in the mouse uterus. N=186 --> 123
- ||||| Kinaction (masitinib) / AB Science
Enrollment change, Metastases: Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit (clinicaltrials.gov) - Feb 7, 2019
P3, N=134, Active, not recruiting, Sponsor: AB Science
N=186 --> 123 N=56 --> 134
- |||| Kinaction (masitinib) / AB Science
Enrollment closed, Metastases: Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit (clinicaltrials.gov) - Feb 4, 2019
P3, N=56, Active, not recruiting, Sponsor: AB Science
N=56 --> 134 Recruiting --> Active, not recruiting
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Stroma: Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib (clinicaltrials.gov) - Feb 4, 2019
P3, N=350, Active, not recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Combination therapy, Metastases: Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients (clinicaltrials.gov) - Feb 4, 2019
P2/3, N=248, Active, not recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed: Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels (clinicaltrials.gov) - Feb 4, 2019
P3, N=345, Active, not recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Combination therapy, Metastases: AB12005: Masitinib Plus Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Feb 4, 2019
P3, N=330, Active, not recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Kinaction (masitinib) / AB Science
Trial primary completion date, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 28, 2019
P2/3, N=219, Active, not recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2018 --> Dec 2020
- |||| Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy, Metastases: AB12005: Masitinib Plus Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Jan 3, 2019
P3, N=330, Recruiting, Sponsor: AB Science
Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Dec 2021 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- ||| Kinaction (masitinib) / AB Science
Trial completion date, Combination therapy, Metastases: Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Dec 30, 2018
P3, N=580, Recruiting, Sponsor: AB Science
Trial completion date: Dec 2021 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Trial completion date: Dec 2021 --> Sep 2020
- | Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Stroma: Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Dec 14, 2018
P3, N=335, Terminated, Sponsor: AB Science
Trial completion date: Dec 2021 --> Sep 2020 N=222 --> 335 | Trial completion date: Dec 2013 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2013 --> Jul 2018; Sponsor decision based on portfolio prioritization
- Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 13, 2018
P3, N=186, Terminated, Sponsor: AB Science
N=222 --> 335 | Trial completion date: Dec 2013 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2013 --> Jul 2018; Sponsor decision based on portfolio prioritization Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Jun 2018 --> Dec 2017
- Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 12, 2018
P3, N=147, Terminated, Sponsor: AB Science
Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Jun 2018 --> Dec 2017 Trial completion date: Jun 2018 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Feb 2017
- Kinaction (masitinib) / AB Science
Trial completion date, Combination therapy: Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 10, 2018
P2b, N=324, Terminated, Sponsor: AB Science
Trial completion date: Jun 2018 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Feb 2017 Trial completion date: Jun 2018 --> Sep 2016
- ||||| Kinaction (masitinib) / AB Science
Enrollment change, Trial primary completion date, Metastases: Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit (clinicaltrials.gov) - Dec 10, 2018
P3, N=56, Recruiting, Sponsor: AB Science
Trial completion date: Jun 2018 --> Sep 2016 N=200 --> 56 | Trial primary completion date: Dec 2017 --> Dec 2019
- Kinaction (masitinib) / AB Science
Phase classification: Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 10, 2018
P2a, N=35, Completed, Sponsor: AB Science
N=200 --> 56 | Trial primary completion date: Dec 2017 --> Dec 2019 Phase classification: P2 --> P2a
- ||| Kinaction (masitinib) / AB Science
Trial completion date, Combination therapy: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Dec 10, 2018
P2/3, N=394, Completed, Sponsor: AB Science
Phase classification: P2 --> P2a Trial completion date: Mar 2017 --> Mar 2018
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial: Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels (clinicaltrials.gov) - Dec 10, 2018
P3, N=345, Recruiting, Sponsor: AB Science
- ||||| Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial primary completion date, Stroma: Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib (clinicaltrials.gov) - Dec 10, 2018
P3, N=350, Recruiting, Sponsor: AB Science
Trial completion date: Mar 2017 --> Mar 2018 N=208 --> 350 | Trial completion date: Dec 2015 --> Dec 2022 | Trial primary completion date: Jan 2015 --> Dec 2021
- || Kinaction (masitinib) / AB Science
Trial completion, Stroma, Metastases: Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST) (clinicaltrials.gov) - Dec 10, 2018
P2, N=30, Completed, Sponsor: AB Science
N=208 --> 350 | Trial completion date: Dec 2015 --> Dec 2022 | Trial primary completion date: Jan 2015 --> Dec 2021 Active, not recruiting --> Completed
- || Kinaction (masitinib) / AB Science
Trial completion: Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 (clinicaltrials.gov) - Dec 10, 2018
P2, N=24, Completed, Sponsor: AB Science
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Kinaction (masitinib) / AB Science
Enrollment change, Combination therapy, Metastases: Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients (clinicaltrials.gov) - Dec 10, 2018
P2/3, N=248, Recruiting, Sponsor: AB Science
Active, not recruiting --> Completed N=68 --> 248
- ||||| Kinaction (masitinib) / AB Science
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (clinicaltrials.gov) - Dec 10, 2018
P3, N=495, Not yet recruiting, Sponsor: AB Science
N=68 --> 248 Trial completion date: Sep 2019 --> May 2024 | Initiation date: Sep 2017 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2021
- ||||| Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial primary completion date: Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids (clinicaltrials.gov) - Dec 7, 2018
P3, N=420, Active, not recruiting, Sponsor: AB Science
Trial completion date: Sep 2019 --> May 2024 | Initiation date: Sep 2017 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2021 N=300 --> 420 | Trial completion date: Dec 2015 --> Mar 2019 | Trial primary completion date: Dec 2013 --> Mar 2019
- || Kinaction (masitinib) / AB Science
Trial completion, Combination therapy: Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2018
P2, N=20, Completed, Sponsor: AB Science
N=300 --> 420 | Trial completion date: Dec 2015 --> Mar 2019 | Trial primary completion date: Dec 2013 --> Mar 2019 Active, not recruiting --> Completed
- Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy: Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2018
P2b, N=324, Terminated, Sponsor: AB Science
Active, not recruiting --> Completed Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Dec 2013 --> Jun 2018
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Phase classification, Enrollment change, Trial completion date: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 6, 2018
P3, N=656, Active, not recruiting, Sponsor: AB Science
Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Dec 2013 --> Jun 2018 Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P3 | N=450 --> 656 | Trial completion date: Jul 2019 --> Mar 2019
- || Kinaction (masitinib) / AB Science
Trial completion, Stroma: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib (clinicaltrials.gov) - Dec 6, 2018
P2, N=44, Completed, Sponsor: AB Science
Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P3 | N=450 --> 656 | Trial completion date: Jul 2019 --> Mar 2019 Active, not recruiting --> Completed
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy, Metastases: AB12005: Masitinib Plus Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Dec 6, 2018
P3, N=330, Recruiting, Sponsor: AB Science
- | Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 5, 2018
P3, N=147, Terminated, Sponsor: AB Science
Active, not recruiting --> Completed N=300 --> 147 | Trial completion date: Dec 2014 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Jun 2018; Sponsor decision based on portfolio prioritization
- | Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Surgery, Stroma: Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence (clinicaltrials.gov) - Dec 5, 2018
P3, N=7, Terminated, Sponsor: AB Science
N=300 --> 147 | Trial completion date: Dec 2014 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Jun 2018; Sponsor decision based on portfolio prioritization N=330 --> 7 | Trial completion date: Dec 2016 --> Jul 2018 | Not yet recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jun 2018; Sponsor decision based on portfolio prioritization
- ||||| Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial primary completion date: Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Dec 5, 2018
P3, N=721, Active, not recruiting, Sponsor: AB Science
N=330 --> 7 | Trial completion date: Dec 2016 --> Jul 2018 | Not yet recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jun 2018; Sponsor decision based on portfolio prioritization N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019
- |||| Kinaction (masitinib) / AB Science
Enrollment open, Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients (clinicaltrials.gov) - Dec 5, 2018
P2/3, N=68, Recruiting, Sponsor: AB Science
N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019 Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | Trial completion date: Jun 2018 --> Dec 2020 | Trial primary completion date: Apr 2018 --> Dec 2020
- | Kinaction (masitinib) / AB Science
Enrollment change, Trial termination, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2018
P3, N=186, Terminated, Sponsor: AB Science
Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | Trial completion date: Jun 2018 --> Dec 2020 | Trial primary completion date: Apr 2018 --> Dec 2020 N=550 --> 186 | Recruiting --> Terminated; Sponsor decision based on portfolio prioritization
- ||||| Kinaction (masitinib) / AB Science
Trial completion, Enrollment change: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis (clinicaltrials.gov) - Dec 3, 2018
P3, N=135, Completed, Sponsor: AB Science
N=550 --> 186 | Recruiting --> Terminated; Sponsor decision based on portfolio prioritization Recruiting --> Completed | N=200 --> 135
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 3, 2018
P2/3, N=219, Active, not recruiting, Sponsor: AB Science
Recruiting --> Completed | N=200 --> 135 Recruiting --> Active, not recruiting
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy, Metastases: Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Dec 3, 2018
P3, N=580, Recruiting, Sponsor: AB Science
- | Kinaction (masitinib) / AB Science
Trial completion, Combination therapy, Metastases: Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 29, 2018
P3, N=353, Completed, Sponsor: AB Science
Recruiting --> Active, not recruiting Active, not recruiting --> Completed